Pharmacist Catch of the Month

Published Online: Wednesday, November 1, 2006

Digoxin Toxicity

Two doctor of pharmacy candidates saw a patient in a pharmacist-run anticoagulation clinic for an initial visit. The patient was taking warfarin and digoxin daily following a recent diagnosis of atrial flutter. He stated that he had felt nauseous after taking the medications and had several episodes of vomiting. The patient also complained of having blurred vision for a couple of days. Upon questioning, it was learned that the blurred vision could be described as halos.

Digoxin toxicity was suspected. A digoxin level test was ordered. The result was 2.4 ng/mL (range 0.8-2.0 ng/mL).

The pharmacist preceptor had the patient hold the dose for 2 days, then restarted the patient on a lower dose. At the patient's next visit, his symptoms had resolved.

Lovenox Not Needed

A patient was admitted to the intensive care unit (ICU) for chest pain to rule out acute coronary syndrome. The patient was started on Lovenox (enoxaparin) 60 mg sq bid. The cardiac workup was normal. There was no elevation of cardiac enzymes, and the echocardiogram was negative. During ICU rounds, an intern noted that the chest pain was relieved with protonix but not with nitroglycerin (NTG) sublingual tablets (the patient had taken the NTG prior to admission).

A pharmacist recommended stopping the Lovenox, because acute coronary syndrome had been ruled out. This discontinuation has resulted in cost savings ($31 per dose) and a reduction of bleeding risk.

Pharmacy Times has introduced this new feature that highlights hospital pharmacists' error-averting actions. We encourage readers to submit their own "catches" for this column to:

Latest Articles
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Anxiety sensitivity has been linked to more debilitating asthma symptoms and greater functional limitations.
Nasal corticosteroid sprays do not seem to be viable treatments for the common cold.
Latest Issues